Dieci MV - Search Results

1

Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors.

Caprara G, Tieri M, Fabi A, Guarneri V, Falci C, Dieci MV, Turazza M, Ballardini B, Bin A, Cinieri S, Vici P, Montagna E, Zamagni C, Mazzi C, Modena A, Marchetti F, Verzè M, Ghelfi F, Titta L, Nicolis F, Gori S. Caprara G, et al. Among authors: dieci mv. Front Oncol. 2021 Nov 1;11:705927. doi: 10.3389/fonc.2021.705927. eCollection 2021. Front Oncol. 2021. PMID: 34804915 Free PMC article.

2

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.

Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Guarneri V, et al. Among authors: dieci mv. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0. Cancer Treat Rev. 2010. PMID: 21129613 Review.

3

Timing for starting second-line therapy in recurrent ovarian cancer.

Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Guarneri V, et al. Among authors: dieci mv. Expert Rev Anticancer Ther. 2011 Jan;11(1):49-55. doi: 10.1586/era.10.204. Expert Rev Anticancer Ther. 2011. PMID: 21166510 Review.

4

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

Guarneri V, Dieci MV, Conte P. Guarneri V, et al. Among authors: dieci mv. Expert Opin Pharmacother. 2012 Feb;13(3):395-406. doi: 10.1517/14656566.2012.651127. Epub 2012 Jan 21. Expert Opin Pharmacother. 2012. PMID: 22263900 Review.

5

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.

Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Dieci MV, et al. Ann Oncol. 2013 Jan;24(1):101-8. doi: 10.1093/annonc/mds248. Epub 2012 Sep 20. Ann Oncol. 2013. PMID: 23002281 Free article.

6

Relapsed triple-negative breast cancer: challenges and treatment strategies.

Guarneri V, Dieci MV, Conte P. Guarneri V, et al. Among authors: dieci mv. Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6. Drugs. 2013. PMID: 23842749 Review.

7

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Guarneri V, et al. Among authors: dieci mv. Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7. Ann Oncol. 2013. PMID: 24013581 Free article.

8

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.

9

Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.

Falci C, Dieci MV, Guarneri V, Soldà C, Bria E, Tortora G, Conte P. Falci C, et al. Among authors: dieci mv. Expert Rev Anticancer Ther. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23. Expert Rev Anticancer Ther. 2014. PMID: 24953376 Review.

10

Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Dieci MV, et al. Oncologist. 2014 Aug;19(8):805-13. doi: 10.1634/theoncologist.2014-0108. Epub 2014 Jun 26. Oncologist. 2014. PMID: 24969162 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page